Suchergebnisse - "Immunosuppressive Agents"

1

Pharmacology of Immunosuppression

Erschienen: Cham, Springer, 2022

Handbook of Experimental Pharmacology Ser - v.272

von Eisen, H.

2

Pharmacology of Immunosuppression

Erschienen: Cham, Springer International Publishing AG, 2022

Handbook of Experimental Pharmacology Series - v.272

1st ed.

von Eisen, H.

3

Clinical review report : indication : indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, June 2020

CADTH common drug review

Version: Final.

4

Pharmacoeconomic review report : (UCB Canada Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapyCertolizumab pegol (Cimzia)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2020

CADTH common drug review

Version: Final.

5

Pharmacoeconomic review report : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), CADTH, June 2020

CADTH common drug review

Final (with redactions).

6

CADTH Canadian Drug Expert Committee recommendation : indication: systemic lupus erythematosus (SLE)Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), CADTH, April 2020

CADTH common drug review

7

Clinical review report : (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PEX) and immunosuppressive therapyCaplacizumab (Cablivi)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, October 2020

CADTH common drug review

Final (with redactions).

8

Pathophysiology of ischemia reperfusion injury and use of fingolimod in cardioprotection

Erschienen: London, Academic Press, an imprint of Elsevier, [2019]

von Ahmed, N.

9

Nijkamp and Parnham's Principles of Immunopharmacology

Erschienen: Cham, Springer International Publishing, 2019

Springer eBook Collection

4th ed. 2019.

von Parnham, M. | Nijkamp, F. | Rossi, A.

10

Second-line therapy for patients with relapsing-remitting multiple sclerosis : a review of guidelines

Erschienen: Ottawa (ON), CADTH, September 26, 2019

CADTH rapid response report: summary with critical appraisal

von Li, K. | Picheca, L.

Filter & Sortierung